Proxorphan
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 17-(cyclopropylmethyl)-6-oxamorphinan-3-ol or (1S,9R,10R)-17-(cyclopropylmethyl)-13-oxa-17-azatetracyclo[7.5.3.0~1,10~.0~2,7~]heptadeca-2,4,6-trien-4-ol |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 69815-38-9 |
| ATC code | None |
| ChemSpider | 21476727 |
| UNII | TFE8T279QV  |
| Chemical data | |
| Formula | C19H25NO2 |
| Mol. mass | 299.41 g/mol |
|
|
Proxorphan is an opioid analgesic and antitussive drug of the morphinan family that was never marketed.[1] It acts as a κ-opioid receptor partial agonist and to a lesser extent as a μ-opioid receptor partial agonist.[2][3][4][5]
See also [edit]
References [edit]
- ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9.
- ^ Leander JD (October 1983). "Further study of kappa opioids on increased urination". The Journal of Pharmacology and Experimental Therapeutics 227 (1): 35–41. PMID 6137557.
- ^ Hayes AG, Birch PJ (August 1988). "Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig". Neuropharmacology 27 (8): 813–6. doi:10.1016/0028-3908(88)90096-2. PMID 3216959.
- ^ Picker MJ, Dykstra LA (May 1989). "Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists". The Journal of Pharmacology and Experimental Therapeutics 249 (2): 557–66. PMID 2566680.
- ^ Picker MJ, Craft RM, Negus SS, et al. (November 1992). "Intermediate efficacy mu opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats". The Journal of Pharmacology and Experimental Therapeutics 263 (2): 668–81. PMID 1331411.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||
